Biochemical markers of bone turnover in patients with spinal metastases after resistance training under radiotherapy--a randomized trial

Harald Rief, Georg Omlor, Michael Akbar, Thomas Bruckner, Stefan Rieken, Robert Förster, Ingmar Schlampp, Thomas Welzel, Tilman Bostel, Heinz Jürgen Roth, Jürgen Debus, Harald Rief, Georg Omlor, Michael Akbar, Thomas Bruckner, Stefan Rieken, Robert Förster, Ingmar Schlampp, Thomas Welzel, Tilman Bostel, Heinz Jürgen Roth, Jürgen Debus

Abstract

Background: To compare the effects of resistance training versus passive physical therapy on bone turnover markers (BTM) in the metastatic bone during radiation therapy (RT) in patients with spinal bone metastases. Secondly, to evaluate an association of BTM to local response, skeletal-related events (SRE), and number of metastases.

Methods: In this randomized trial, 60 patients were allocated from September 2011 to March 2013 into one of the two arms: resistance training (Arm A) or passive physical therapy (Arm B) with thirty patients in each arm during RT. Biochemical markers such as pyridinoline (PYD), desoxy-pyridinoline (DPD), bone alkaline phosphatase (BAP), total amino-terminal propeptide of type I collagen (PINP), beta-isomer of carboxy-terminal telopeptide of type I collagen (CTX-I), and cross-linked N-telopeptide of type I collagen (NTX) were analyzed at baseline, and three months after RT.

Results: Mean change values of PYD and CTX-I were significantly lower at 3 months after RT (p = 0.035 and p = 0.043) in Arm A. Importantly, all markers decreased in both arms, except of PYD and CTX-I in arm B, although significance was not reached for some biomarkers. In arm A, the local response was significantly higher (p = 0.003) and PINP could be identified as a predictor for survivors (OR 0.968, 95%CI 0.938-0.999, p = 0.043). BAP (OR 0.974, 95%CI 0.950-0.998, p = 0.034) and PINP (OR 1.025, 95%CI 1.001-1.049, p = 0.044) were related with an avoidance of SRE.

Conclusions: In this group of patients with spinal bone metastases, we were able to show that patients with guided resistance training of the paravertebral muscles can influence BTM. PYD and CTX-I decreased significantly in arm A. PINP can be considered as a complementary tool for prediction of local response, and PINP as well as BAP for avoidance of SRE.

Trial registration: Clinical trial identifier NCT 01409720. August 2, 2011.

Trial registration: ClinicalTrials.gov NCT01409720.

Keywords: Biochemical markers; Bone metastases; Physical exercise; Resistance training; Spine.

Figures

Fig. 1
Fig. 1
Flow of participants through the trial

References

    1. Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 2001;27:165–176. doi: 10.1053/ctrv.2000.0210.
    1. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiol Oncol Biol Phys. 2011;79(4):965–76. doi: 10.1016/j.ijrobp.2010.11.026.
    1. Coleman R, Costa L, Saad F, et al. Consensus on the utility of bone markers in the malignant bone disease setting. Crit Rev Oncol Hematol. 2011;80(3):411–32. doi: 10.1016/j.critrevonc.2011.02.005.
    1. Zhao H, Han KL, Wang ZY, et al. Value of C-telopeptide-cross-linked type I collagen, osteocalcin, bone specific alkaline phosphatase and procollagen type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors. Med Sci Monit. 2011;17(11):626–633. doi: 10.12659/MSM.882047.
    1. Jung K, Lein M, Ringsdorf M, et al. Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. J Urol. 2006;176:1326–31. doi: 10.1016/j.juro.2006.06.028.
    1. Kamiya N, Suzuki H, Yano M, et al. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis. Urology. 2010;75(6):1446–51. doi: 10.1016/j.urology.2009.11.049.
    1. Mountzios G, Terpos E, Syrigos K, et al. Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Transl Res. 2010;155(5):247–55. doi: 10.1016/j.trsl.2010.01.002.
    1. Saad F, Eastham JA, Smith MR. Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. Urol Oncol. 2012;30(4):369–78. doi: 10.1016/j.urolonc.2010.08.007.
    1. Zaghloul MS, Boutrus R, El-Hossieny H, et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15(4):382–9. doi: 10.1007/s10147-010-0074-5.
    1. Rief H, Omlor G, Akbar M, et al. Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial. BMC Cancer. 2014;14:67. doi: 10.1186/1471-2407-14-67.
    1. Karnofsky DA, Burchenal JH (1949) The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM (Ed), Evaluation of Chemotherapeutic Agents. New York, pp191-205.
    1. Taneichi H, Kaneda K, Takeda N, et al. Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine. Spine. 1997;22:239–245. doi: 10.1097/00007632-199702010-00002.
    1. Rief H, Jensen AD, Bruckner T, Herfarth K, Debus J. Isometric muscle training of the spine musculature in patients with spinal bony metastases under radiation therapy. BMC Cancer. 2011;11:482. doi: 10.1186/1471-2407-11-482.
    1. Vesper HW, Audain C, Woolfitt A, et al. High-performance liquid chromatography method to analyze free and total urinary pyridinoline and desoxypyridinoline. Anal Biochem. 2003;318:204–11. doi: 10.1016/S0003-2697(03)00241-0.
    1. Seibel MJ, Lang M, Geilenkeuser WJ. Interlaboratory variation of biochemical markers of bone turnover. Clin Chem. 2001;47:1443–50.
    1. Jung K, Miller K, Wirth M, et al. Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. Eur Urol. 2011;59:604–612. doi: 10.1016/j.eururo.2010.12.006.
    1. Coleman RE, Lipton A, Roodman GD, et al. Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev. 2010;36:615–620. doi: 10.1016/j.ctrv.2010.04.003.
    1. Armstrong AJ, Eisenberger MA, Halabi S, et al. Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. Eur Urol. 2012;61:549–559. doi: 10.1016/j.eururo.2011.11.009.
    1. Rief H, Petersen LC, Omlor G, et al. The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - a randomized trial. Radiother Oncol. 2014;112(1):133–9. doi: 10.1016/j.radonc.2014.06.008.
    1. Alcaraz A, Gonzalez-Lopez R, Morote J, et al. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study. British J cancer. 2013;109:121–130. doi: 10.1038/bjc.2013.272.
    1. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005;23(22):4925–35. doi: 10.1200/JCO.2005.06.091.
    1. Brown JE, Thomson CS, Ellis SP, et al. Bone resorption redicts for skeletal complications in metastatic bone disease. Br J Cancer. 2003;89:2031–2037. doi: 10.1038/sj.bjc.6601437.
    1. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. JNCI. 2005;97:59–69. doi: 10.1093/jnci/dji002.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj